OBI Pharma Inc. announces the change of VP, Chief Medical Officer

To clarify the media report
July 1, 2016
To clarify the media report
August 31, 2016

1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel(CEO, COO, CMO, CSO, etc.),financial officer, accounting officer, research and development officer, or internal audit officer): VP, Chief Medical Officer
2.Date of occurrence of the change:2016/08/10
3.Name, title, and resume of the replaced person: Nathan Chen, VP, Chief Medical Officer
4.Name, title, and resume of the replacement: NA
5.Type of the change (please enter: “resignation”, “position adjustment”, “dismissal”, “retirement”, “death” or “new replacement” ): resignation
6.Reason for the change: Individual career planning
7.Effective date:2016/08/10
8.Contact telephone number of the replacement: (02)2786-6589
9.Any other matters that need to be specified:
(1)Dr. Nathan Chen will continue to be deeply involved in the success of OBI Pharma and will join the company’s Medical Advisory Board on August 11th, 2016.
(2)OBI’s Clinical Development, at current stage, will be led by Vice President of Global Clinical Development and Medical Affairs, Dr. Cristina Chang